Abstract
COVID-19 manifests with a wide spectrum of clinical phenotypes that are characterized by exaggerated and misdirected host immune responses1–8. While pathological innate immune activation is well documented in severe disease1, the impact of autoantibodies on disease progression is less defined. Here, we used a high-throughput autoantibody discovery technique called Rapid Extracellular Antigen Profiling (REAP) to screen a cohort of 194 SARS-CoV-2 infected COVID-19 patients and healthcare workers for autoantibodies against 2,770 extracellular and secreted proteins (the “exoproteome”). We found that COVID-19 patients exhibit dramatic increases in autoantibody reactivities compared to uninfected controls, with a high prevalence of autoantibodies against immunomodulatory proteins including cytokines, chemokines, complement components, and cell surface proteins. We established that these autoantibodies perturb immune function and impair virological control by inhibiting immunoreceptor signaling and by altering peripheral immune cell composition, and found that murine surrogates of these autoantibodies exacerbate disease severity in a mouse model of SARS-CoV-2 infection. Analysis of autoantibodies against tissue-associated antigens revealed associations with specific clinical characteristics and disease severity. In summary, these findings implicate a pathological role for exoproteome-directed autoantibodies in COVID-19 with diverse impacts on immune functionality and associations with clinical outcomes.
Competing Interest Statement
A.M.R., E.Y.W., and Y.D. are inventors of a patent describing the REAP technology.
Funding Statement
This work was supported by the Mathers Family Foundation (to A.M.R. and A.I.), the Ludwig Family Foundation (to A.M.R. and A.I.), a supplement to the Yale Cancer Center Support Grant 3P30CA016359-40S4 (to A.M.R), the Beatrice Neuwirth Foundation, Yale Schools of Medicine and Public Health and NIAID grant U19 AI08992. IMPACT received support from the Yale COVID-19 Research Resource Fund. A.M.R. is additionally supported by an NIH Director's Early Independence Award (DP5OD023088) and the Robert T. McCluskey Foundation. T.M. is supported by the Yale Interdisciplinary Immunology Training Program T32AI007019. J.K. is supported by the Yale Medical Scientist Training Program T32GM007205. C.B.F.V. is supported by NWO Rubicon (no. 019.181EN.004).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵¶ A list of authors and their affiliations appears at the end of the paper
Main figures were reformatted for readability.
Data Availability
All non PHI data in the manuscript will be made available upon request.
